BioCardia (BCDA) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 05, 2019
Document Information [Line Items]
Entity Registrant Name	BioCardia, Inc.
Entity Central Index Key	0000925741
Trading Symbol	bcda
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		4,847,471
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 517,000	$ 5,358,000
Accounts receivable, net of allowance for doubtful accounts of $14 and $9 at June 30, 2019 and December 31, 2018	204,000	274,000
Inventory	5,000	141,000
Short-term investments
Prepaid expenses and other current assets	426,000	445,000
Total current assets	1,152,000	6,218,000
Property and equipment, net	218,000	145,000
Operating lease right-of-use asset, net	1,292,000
Other assets	54,000	54,000
Total assets	2,716,000	6,417,000
Current liabilities:
Accounts payable	1,626,000	1,020,000
Accrued expenses and other current liabilities	1,952,000	1,528,000
Operating lease liability - current	488,000
Total current liabilities	4,066,000	2,548,000
Operating lease liability - noncurrent	886,000
Deferred rent		77,000
Total liabilities	4,952,000	2,625,000
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized as of June 30, 2019 and December 31, 2018; no shares issued and outstanding as of June 30, 2019 and December 31, 2018
Common stock, $0.001 par value, 100,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 4,847,471 and 4,845,697 shares issued and outstanding as of June 30, 2019 and December 31, 2018	44,000	43,000
Additional paid-in capital	91,496,000	90,110,000
Accumulated deficit	(93,776,000)	(86,361,000)
Total stockholders’ (deficit) equity	(2,236,000)	3,792,000
Total liabilities and stockholders’ equity	$ 2,716,000	$ 6,417,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 14	$ 9
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	4,847,471	4,845,697
Common stock, shares outstanding (in shares)	4,847,471	4,845,697

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Total revenue	$ 86	$ 239	$ 302	$ 438
Costs and expenses:
Cost of goods sold	191	135	297	292
Research and development	2,219	2,031	4,385	3,986
Selling, general and administrative	1,438	1,325	3,070	3,032
Total costs and expenses	3,848	3,491	7,752	7,310
Operating loss	(3,762)	(3,252)	(7,450)	(6,872)
Other income (expense):
Interest income	13	35	36	71
Other expense	(1)		(1)
Total other income	12	35	35	71
Net loss	$ (3,750)	$ (3,217)	$ (7,415)	$ (6,801)
Net loss per share, basic and diluted (in dollars per share)	$ (0.77)	$ (0.76)	$ (1.53)	$ (1.60)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	4,847,829	4,249,698	4,847,746	4,249,192
Product [Member]
Revenue:
Total revenue	$ 62	$ 89	$ 139	$ 171
Collaboration Agreement [Member]
Revenue:
Total revenue	$ 24	$ 150	$ 163	$ 267

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	4,246,519
Balance at Dec. 31, 2017	$ 38	$ 83,537	$ (72,450)	$ 11,125
Restricted stock units vested and issued (in shares)	2,271
Restricted stock units vested and issued
Share-based compensation		615		615
Net loss			(3,584)	(3,584)
Balance (in shares) at Mar. 31, 2018	4,249,027
Balance at Mar. 31, 2018	$ 38	84,157	(75,988)	8,207
Adjustments to opening balance for change in accounting principle			46	46
Exercise of stock options (in shares)	237
Exercise of stock options		5		5
Balance (in shares) at Dec. 31, 2017	4,246,519
Balance at Dec. 31, 2017	$ 38	83,537	(72,450)	11,125
Net loss				(6,801)
Balance (in shares) at Jun. 30, 2018	4,253,100
Balance at Jun. 30, 2018	$ 38	84,895	(79,175)	5,758
Balance (in shares) at Mar. 31, 2018	4,249,027
Balance at Mar. 31, 2018	$ 38	84,157	(75,988)	8,207
Restricted stock units vested and issued (in shares)	4,073
Restricted stock units vested and issued
Share-based compensation		738		738
Net loss			(3,217)	(3,217)
Balance (in shares) at Jun. 30, 2018	4,253,100
Balance at Jun. 30, 2018	$ 38	84,895	(79,175)	5,758
Adjustments to opening balance for change in accounting principle			30	30
Balance (in shares) at Dec. 31, 2018	4,845,697
Balance at Dec. 31, 2018	$ 43	90,110	(86,361)	3,792
Restricted stock units vested and issued (in shares)	2,268
Restricted stock units vested and issued	$ 1			1
Share-based compensation		690		690
Net loss			(3,665)	(3,665)
Balance (in shares) at Mar. 31, 2019	4,847,965
Balance at Mar. 31, 2019	$ 44	90,800	(90,026)	818
Balance (in shares) at Dec. 31, 2018	4,845,697
Balance at Dec. 31, 2018	$ 43	90,110	(86,361)	3,792
Net loss				(7,415)
Balance (in shares) at Jun. 30, 2019	4,847,471
Balance at Jun. 30, 2019	$ 44	91,496	(93,776)	$ (2,236)
Exercise of stock options (in shares)
Balance (in shares) at Mar. 31, 2019	4,847,965
Balance at Mar. 31, 2019	$ 44	90,800	(90,026)	$ 818
Share-based compensation		696		696
Net loss			(3,750)	(3,750)
Balance (in shares) at Jun. 30, 2019	4,847,471
Balance at Jun. 30, 2019	$ 44	$ 91,496	$ (93,776)	$ (2,236)
Reverse stock split fractional share true up (in shares)	(494)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net loss	$ (7,415,000)	$ (6,801,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Write-off of inventory	52,000
Depreciation and amortization	49,000	44,000
Amortization of right-of-use asset	213,000
Share-based compensation	1,386,000	1,353,000
Changes in operating assets and liabilities:
Accounts receivable	70,000	(96,000)
Inventory	85,000	55,000
Prepaid expenses and other current assets	18,000	58,000
Accounts payable	609,000	(390,000)
Accrued expenses and other current liabilities	472,000	25,000
Deferred revenue		(65,000)
Deferred rent		3,000
Operating lease liability - noncurrent	(256,000)
Net cash used in operating activities	(4,717,000)	(5,814,000)
Investing activities:
Purchase of property and equipment	(124,000)	(46,000)
Net cash used in investing activities	(124,000)	(46,000)
Financing activities:
Proceeds from the exercise of common stock options		5,000
Net cash provided by financing activities		5,000
Net change in cash and cash equivalents	(4,841,000)	(5,855,000)
Cash and cash equivalents at beginning of period	5,358,000	12,689,000
Cash and cash equivalents at end of period	$ 517,000	$ 6,834,000

Note 1 - Summary of Business an

Note 1 - Summary of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	( 1 Summary of Business and Basis of Presentation (a) Description of Business BioCardia, Inc., (BioCardia or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The Company’s lead therapeutic candidate is the CardiAMP® cell therapy system and its second BioCardia also has three 1 2 ™ 3 ™

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	( 2 Significant Accounting Policies (a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, shareholders equity, and cash flows as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly its financial position as of June 30, 2019, results of operations for the three and six months ended June 30, 2019 and 2018, and cash flows for the six months ended June 30, 2019 and 2018. The results for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any other future year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10 -K for the year ended December 31, 2018, filed with the SEC on April 2, 2019. (b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $93.8 million as of June 30, 2019. Management expects operating losses and negative cash flows to continue through the next several years. These factors raise substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date these financial statements are issued. Based on management’s current plans, management believes cash and cash equivalents of $517,000 as of June 30, 2019, together with the $625,000 in proceeds received from the convertible promissory notes issued in July 2019 and the $8.76 million in net cash received from the public offering in August ( see Note 13 ), may not be sufficient to fund the Company for one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If adequate funds are not available, BioCardia may be required to reduce operating expenses, delay or reduce the scope of its product development programs, obtain funds through arrangements with others that may require it to relinquish rights to certain of its technologies or products that the Company would otherwise seek to develop or commercialize itself, or cease operations. While the Company believes it has a viable strategy to raise additional funds, there can be no assurances that it will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund its operating needs. (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns, incremental borrowing rate, and inventory valuation. (d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process. (e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in its Annual Report on Form 10 -K filed for the year ended December 31, 2018. Apart from the adoption of ASU No. 2018 - 07, Compensation–Stock Compensation (Topic 718 ): Improvements to Nonemployee Share-based Payment Accounting on January 1, 2019, which led to an amended stock-based compensation policy, and the adoption of ASU No. 2016 - 02, Leases (Topic 842 ), which led to an amended lease policy as described in the following paragraphs, there have been no changes to those policies. Measurement of nonemployee awards - The measurement of equity-classified nonemployee awards is fixed at the grant date, and the Company may use the expected term to measure nonemployee options or elect to use the contractual term as the expected term, on an award-by-award basis. This differs from the guidance in ASC 505 - 50 that requires the use of the contractual term. Forfeitures of nonemployee awards will be recognized as they occur. Operating lease right-of-use asset and liabilities - The Company will determine if an arrangement is a lease at the inception of the arrangement. All leases are assessed for classification as an operating lease or finance lease. The Company will recognize a lease liability and a ROU asset for all leases, including operating leases, with a term greater than 12 months. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not included the computation of the lease liability. The lease liability discount rate is generally the Company’s incremental borrowing rate unless the lessor’s rate implicit in the lease is readily determinable, in which case the lessor’s implicit rate is used. The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company amortizes a right-of-use (ROU) asset, and the periodic amortization is the difference between the straight-line total lease cost for the period (including amortization of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise any such options. Operating lease cost for lease payments is recognized on a straight-line basis over the lease term. The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not separate lease from non-lease components and accounts for them as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for leases with a term of twelve months or less. Lease cost for short-term leases is recognized on a straight-line basis over the lease term. (f) Recently Adopted Accounting Pronouncement In February 2016, the FASB amended its guidance related to lease accounting. The amended guidance required lessees to recognize a majority of their leases on the balance sheet as a ROU asset and a lease liability. In July 2018, the FASB issued ASU No. 2018 - 11, Leases (Topic 842 ): Targeted Improvements, or ASU No. 2018 - 11. In issuing ASU No. 2018 - 11, the FASB is permitting another transition method for ASU 2016 - 02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company elected this available transition method. The Company adopted the new standard using the cumulative-effect method on January 1, 2019. The Company's adoption included lease codification improvements that were issued by the FASB through March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 months or less off the consolidated balance sheet, and to recognize the associated lease payments in the statements of operations on a straight-line basis over the lease term. The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the Condensed Consolidated Balance Sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 and $1,593,000 respectively, related to operating lease commitments, as of January 1, 2019. The operating lease ROU asset represents the lease liability, plus any lease payments made at or before the commencement date, less any lease incentives received. The amended guidance did not have a material impact on the Company's cash flows or results of operations. See Note 6 of the condensed consolidated financial statements. In June 2018, the FASB issued ASU No. 2018 - 07, Stock Compensation (Topic 718 ): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018 - 07 is intended to reduce the cost and complexity and to improve financial reporting for nonemployee share-based payments. ASU 2018 - 07 expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. No longer will nonemployee awards be marked-to-market every reporting period, nor will the expected term be required to be the contractual term. However, forfeitures will continue to be recognized when incurred. ASU 2018 - 07 supersedes Subtopic 505 - 50, Equity-Based Payments to Non-Employees. The Company adopted ASU 2018 - 07 effective January 1, 2019 using the cumulative-effect method for equity-classified nonemployee awards which have not been settled as of the adoption date. The cumulative effect did not have a material impact on the condensed consolidated balance sheet, statement of operations or statement of cash flows. (g) Recently Issued Accounting Pronouncements Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force did not or are not believed by management to have a material impact on the Company’s financial statement presentation or disclosures.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	( 3 The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of its financial assets measured on a recurring basis as of June 30, 2019 December 31, 2018 As of June 30, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 517 $ — $ — $ 517 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	( 4 Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands): June 30, December 31, 2019 2018 Raw materials $ — $ 79 Work in process — 39 Finished goods 5 23 Total $ 5 $ 141 Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $78,000, $80,000 three six June 30, 2019, $12,000, $15,000 three six June 30, 2018,

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	( 5 Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2019 2018 Computer equipment and software $ 124 119 Laboratory and manufacturing equipment 548 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 53 3 Property and equipment, gross 1,112 990 Less accumulated depreciation (894 ) (845 ) Property and equipment, net $ 218 145 Depreciation expense totaled approximately $26,000 $49,000 three six June 30, 2019, $22,000 $44,000 three six June 30, 2018,

Note 6 - Operating Lease Right-

Note 6 - Operating Lease Right-of-use Asset, Net	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 6 The Company adopted the new lease standard on January 1, 2019 not The Company determines if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company’s operating lease is primarily related to a property lease for its laboratory and corporate offices. BioCardia’s lease agreement does not ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company’s lease does not not no not The impact of the new lease standard on the three six June 30, 2019 Three months ended June 30, Six months ended June 30, 2019 2019 Straight-line rent expense recognized for operating lease $ 150 $ 301 Variable rent expense recognized for operating lease 63 138 $ 213 $ 439 Weighted average remaining lease term (in years) 2.5 Weighted average discount rate 12.05 % Supplemental cash flow information related to the operating lease was as follows (in thousands): Three months ended June 30, Six months ended June 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities $ 153 $ 306 Cash Lease Expense (imputed interest expense component of net income) 42 87 Future minimum lease payments under the operating lease as of June 30, 2019 Operating Lease June 30,2019 Remainder of 2019 $ 306 Years ending December 31, 2020 630 2021 649 Total undiscounted lease payments 1,585 Less imputed interest 211 Total operating lease liabilities $ 1,374 Prior to the Company’s adoption of the new lease standard, future minimum lease payments as of December 31, 2018, Years ending December 31, 2019 $ 612 2020 630 2021 649 Total $ 1,891

Note 7 - Accrued Expenses and O

Note 7 - Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]	( 7 Accrued expenses and other current liabilities consisted of the following (in thousands): June 30, December 31, 2019 2018 Accrued expenses $ 739 $ 495 Accrued clinical trial costs 474 276 Grant liability 635 645 Customer deposits 104 112 Total $ 1,952 $ 1,528

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	( 8 Stockholders’ Equity Public Offering on Form S- 1 Registration Statement April 2019, 1 1 August 2, 2019, 1, 1,666,667 one $0.001 one $6.00 $6.30 five 45 250,000 250,000 August 6, 2019. $8.76 $10.15 July 5, 2019, $625,000 14.0% 210,887 one one $3.00 13 Reverse Stock Split June 6, 2019 1 9 Warrants for Common Stock December 24, 2018, 296,296 592,592 $6.75 $3.8 $200,000 six $6.75 December 24, 2023.

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	( 9 ) Share-Based Compensation The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's or non-employee’s respective function. No three six June 30, 2019 2018 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Cost of goods sold $ 46 $ 36 $ 92 $ 66 Research and development 251 264 494 461 Selling, general and administrative 399 438 800 826 Share-based compensation expense $ 696 $ 738 $ 1,386 $ 1,353 The following table summarizes the activity of stock options and related information: Options outstanding Number of shares Weighted average exercise price Balance, December 31, 2018 608,485 $ 25.16 Stock options granted 14,000 10.05 Stock options exercised — - Stock options canceled (4,119 ) 45.10 Balance, June 30, 2019 618,366 $ 24.75 Exercisable and vested, June 30, 2019 362,368 $ 24.57 Unrecognized share-based compensation for employee and nonemployee options granted through June 30, 2019 $3.9 2.0 Non-Employee Director Share-Based Compensation (RSUs) The following summarizes the activity of non-vested RSUs: Weighted average grant date Number of fair value shares per share Stock options canceled 29,694 $ 25.56 RSUs granted - - RSUs vested (2,268 ) $ 99.36 RSUs forfeited - - Balance, June 30, 2019 27,426 $ 19.45 Unrecognized share-based compensation for RSUs granted through June 30, 2019 $148,000 0.5

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	( 10 Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: June 30, 2019 2018 Stock options to purchase common stock 618,366 630,911 Unvested restricted stock units 27,426 4,543 Common stock warrants 296,296 - Total 942,088 635,454

Note 11 - Income Taxes

Note 11 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 11 During the three six June 30, 2019 2018, no As of June 30, 2019, not not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	( 12 In August 2016, 46,553 4 $16.20 $22,000 $44,000 three six June 30, 2019, $37,000 $62,000 three six June 30, 2018, $5.3 4 one 5%

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	( 13 On July 5, 2019, $625,000 14.0% August 6, 2019 $633,000, 210,887 one one $3.00 On July 11, 2019, 2017 not $1,000,000 August 13, 2019, On August 2, 2019, 1, 1,666,667 one $0.001 one $6.00 $6.30 five $6.00 $10.0 $8.76 $635,000 $610,000. 45 250,000 250,000 On August 2, 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	(a) Basis of Preparation The accompanying condensed consolidated balance sheets, statements of operations, shareholders equity, and cash flows as of June 30, 2019 three six June 30, 2019 2018 June 30, 2019, three six June 30, 2019 2018, six June 30, 2019 2018. six June 30, 2019 not December 31, 2019 These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10 December 31, 2018, April 2, 2019.
Going Concern and Liquidity [Policy Text Block]	(b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $93.8 June 30, 2019. one $517,000 June 30, 2019, $625,000 July 2019 $8.76 August ( 13 may not one not If adequate funds are not may may no
Use of Estimates, Policy [Policy Text Block]	(c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns, incremental borrowing rate, and inventory valuation.
Consolidation, Policy [Policy Text Block]	(d) Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.
Change to Significant Accounting Policies [Policy Text Block]	(e) Changes to Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 10 December 31, 2018. No. 2018 07, 718 January 1, 2019, No. 2016 02, 842 no Measurement of nonemployee awards may 505 50 Operating lease right-of-use asset and liabilities 12 The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company amortizes a right-of-use (ROU) asset, and the periodic amortization is the difference between the straight-line total lease cost for the period (including amortization of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve
New Accounting Pronouncements, Policy [Policy Text Block]	(f) Recently Adopted Accounting Pronouncement In February 2016, July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, The Company adopted the new standard using the cumulative-effect method on January 1, 2019. March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the Condensed Consolidated Balance Sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 $1,593,000 January 1, 2019. not 6 In June 2018, No. 2018 07, 718 2018 07 2018 07 718, No 2018 07 505 50, 2018 07 January 1, 2019 not not (g) Recently Issued Accounting Pronouncements Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force did not not

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of June 30, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 517 $ — $ — $ 517 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, 2019 2018 Raw materials $ — $ 79 Work in process — 39 Finished goods 5 23 Total $ 5 $ 141

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, December 31, 2019 2018 Computer equipment and software $ 124 119 Laboratory and manufacturing equipment 548 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 53 3 Property and equipment, gross 1,112 990 Less accumulated depreciation (894 ) (845 ) Property and equipment, net $ 218 145

Note 6 - Operating Lease Righ_2

Note 6 - Operating Lease Right-of-use Asset, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2019 Straight-line rent expense recognized for operating lease $ 150 $ 301 Variable rent expense recognized for operating lease 63 138 $ 213 $ 439 Weighted average remaining lease term (in years) 2.5 Weighted average discount rate 12.05 %
Schedule of Operating Leases Cash Flow Information [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities $ 153 $ 306 Cash Lease Expense (imputed interest expense component of net income) 42 87
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Lease June 30,2019 Remainder of 2019 $ 306 Years ending December 31, 2020 630 2021 649 Total undiscounted lease payments 1,585 Less imputed interest 211 Total operating lease liabilities $ 1,374
Lessee, Operating Lease, Disclosure [Table Text Block]	Years ending December 31, 2019 $ 612 2020 630 2021 649 Total $ 1,891

Note 7 - Accrued Expenses and_2

Note 7 - Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]	<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 45pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">739</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical trial costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">474</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">635</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,952</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,528</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>" id="sjs-B4">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt">&lt;table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 45pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> &lt;tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">June 30,&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">December 31,&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">2019&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&lt;div style="display: inline; font-weight: bold;">&lt;div style="display: inline; font-weight: bold;">2018&lt;/div>&lt;/div>&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">739&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">495&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical trial costs&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">474&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grant liability&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">635&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer deposits&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,952&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$&lt;/td> &lt;td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,528&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;/table>&lt;/div>

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Share-based Compensation, Expense [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Cost of goods sold $ 46 $ 36 $ 92 $ 66 Research and development 251 264 494 461 Selling, general and administrative 399 438 800 826 Share-based compensation expense $ 696 $ 738 $ 1,386 $ 1,353
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Options outstanding Number of shares Weighted average exercise price Balance, December 31, 2018 608,485 $ 25.16 Stock options granted 14,000 10.05 Stock options exercised — - Stock options canceled (4,119 ) 45.10 Balance, June 30, 2019 618,366 $ 24.75 Exercisable and vested, June 30, 2019 362,368 $ 24.57
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted average grant date Number of fair value shares per share Stock options canceled 29,694 $ 25.56 RSUs granted - - RSUs vested (2,268 ) $ 99.36 RSUs forfeited - - Balance, June 30, 2019 27,426 $ 19.45

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2019 2018 Stock options to purchase common stock 618,366 630,911 Unvested restricted stock units 27,426 4,543 Common stock warrants 296,296 - Total 942,088 635,454

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Details Textual) - USD ($)	Aug. 02, 2019	Jul. 05, 2019	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit), Ending Balance			$ (93,776,000)		$ (86,361,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance			517,000		5,358,000	$ 6,834,000	$ 12,689,000
Operating Lease, Right-of-Use Asset			1,292,000	$ 1,505,000
Operating Lease, Liability, Total			$ 1,374,000	$ 1,593,000
Subsequent Event [Member] | Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 8,760,000
Convertible Promissory Note [Member] | Subsequent Event [Member]
Proceeds from Convertible Debt		$ 625,000

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets:
Money market funds	$ 517	$ 5,358
Fair Value, Inputs, Level 1 [Member]
Assets:
Money market funds	517	5,358
Fair Value, Inputs, Level 2 [Member]
Assets:
Money market funds
Fair Value, Inputs, Level 3 [Member]
Assets:
Money market funds

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Inventory Write-down			$ 52,000
Cost of Goods Sold [Member]
Inventory Write-down	$ 78,000	$ 12,000	$ 80,000	$ 15,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw materials		$ 79
Work in process		39
Finished goods	5	23
Total	$ 5	$ 141

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Depreciation, Total	$ 26,000	$ 22,000	$ 49,000	$ 44,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 1,112	$ 990
Less accumulated depreciation	(894)	(845)
Property and equipment, net	218	145
Computer Equipment and Software [Member]
Property and equipment, gross	124	119
Laboratory and Manufacturing Equipment [Member]
Property and equipment, gross	548	481
Furniture and Fixtures [Member]
Property and equipment, gross	55	55
Leasehold Improvements [Member]
Property and equipment, gross	332	332
Construction in Progress [Member]
Property and equipment, gross	$ 53	$ 3

Note 6 - Operating Lease Righ_3

Note 6 - Operating Lease Right-of-use Asset, Net - Impact of New Lease Standard (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Straight-line rent expense recognized for operating lease	$ 150	$ 301
Variable rent expense recognized for operating lease	63	138
	$ 213	$ 439
Weighted average remaining lease term (in years) (Year)	2 years 182 days	2 years 182 days
Weighted average discount rate	12.05%	12.05%

Note 6 - Operating Lease Righ_4

Note 6 - Operating Lease Right-of-use Asset, Net - Supplement Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities	$ 153	$ 306
Cash Lease Expense (imputed interest expense component of net income)	$ 42	$ 87

Note 6 - Operating Lease Righ_5

Note 6 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019
Remainder of 2019	$ 306,000
2020	630,000
2021	649,000
Total undiscounted lease payments	1,585,000
Less imputed interest	211,000
Total operating lease liabilities	$ 1,374,000	$ 1,593,000

Note 6 - Operating Lease Righ_6

Note 6 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 612
2020	630
2021	649
Total	$ 1,891

Note 7 - Accrued Expenses and_3

Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued expenses	$ 739	$ 495
Accrued clinical trial costs	474	276
Grant liability	635	645
Customer deposits	104	112
Total	$ 1,952	$ 1,528

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Details Textual)	Aug. 06, 2019$ / sharesshares	Aug. 02, 2019USD ($)$ / sharesshares	Jul. 05, 2019USD ($)	Jun. 06, 2019	Dec. 24, 2018USD ($)$ / sharesshares	Jun. 30, 2019$ / sharesshares	Dec. 31, 2018$ / sharesshares
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 6.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					296,296
Common Stock, Shares, Issued, Total					592,592	4,847,471	4,845,697
Sale of Stock, Price Per Share | $ / shares					$ 6.75
Proceeds from Issuance of Common Stock and Warrants | $					$ 3,800,000
Payments of Stock Issuance Costs | $					$ 200,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				9
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001
Subsequent Event [Member] | Convertible Promissory Note [Member]
Proceeds from Convertible Debt | $			$ 625,000
Debt Instrument, Interest Rate, Stated Percentage			14.00%
Subsequent Event [Member] | Public Offering [Member]
Number of Units Offered to Sale		1,666,667
Number of Common Stock in Each Unit		1
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001
Number of Common Stock Called by Each Unit		1
Unit Offering Price | $ / shares		$ 6
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 6.30
Warrants and Rights Outstanding, Term		5 years
Underwriters, Additional Common Shares Authorized to Purchase		250,000
Underwriters, Additional Warrants Authorized to Purchase		250,000
Proceeds from Issuance or Sale of Equity, Total | $		$ 8,760,000
Proceeds from Issuance or Sale of Equity if Over-allotment Option is Exercised | $		$ 10,150,000
Number of Warrants in Each Unit		1
Subsequent Event [Member] | Private Placement Unit [Member]
Number of Common Stock in Each Unit	1
Number of Common Stock Called by Each Unit	1
Debt Conversion, Converted Instrument, Units	210,887
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 3
Number of Warrants in Each Unit	1

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Amount Capitalized	$ 0	$ 0	$ 0	$ 0
Non-employee Directors and Employees [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	3,900,000		$ 3,900,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 148,000		$ 148,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			182 days

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based compensation expense	$ 696	$ 738	$ 1,386	$ 1,353
Cost of Goods Sold [Member]
Share-based compensation expense	46	36	92	66
Research and Development Expense [Member]
Share-based compensation expense	251	264	494	461
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	$ 399	$ 438	$ 800	$ 826

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Stock options outstanding, beginning of period (in shares) | shares	608,485
Balance, weighted average exercise price, beginning of period (in dollars per share) | $ / shares	$ 25.16
Stock options granted (in shares) | shares	14,000
Stock options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 10.05
Stock options exercised (in shares) | shares
Stock options exercised, weighted average exercise price (in dollars per share) | $ / shares
Stock options canceled (in shares) | shares	(4,119)
Stock options canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 45.10
Balance, June 30, 2019 (in shares) | shares	618,366
Balance, June 30, 2019 (in dollars per share) | $ / shares	$ 24.75
Exercisable and vested (in shares) | shares	362,368
Exercisable and vested, weighted average exercise price (in dollars per share) | $ / shares	$ 24.57

Note 9 - Share-based Compensa_6

Note 9 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Stock options canceled (in shares) | shares	29,694
Stock options canceled (in dollars per share) | $ / shares	$ 25.56
RSUs granted, shares (in shares) | shares
RSUs granted, weighted average grant date fair value per share (in dollars per share) | $ / shares
RSUs vested, shares (in shares) | shares	(2,268)
RSUs vested, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 99.36
RSUs forfeited, shares (in shares) | shares
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares
Balance, June 30, 2019 (in shares) | shares	27,426
Balance, June 30, 2019 (in dollars per share) | $ / shares	$ 19.45

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities (in shares)	942,088	635,454
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	618,366	630,911
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	27,426	4,543
Warrant [Member]
Antidilutive securities (in shares)	296,296

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0	$ 0

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 31, 2016	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				14,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance		$ 24.75		$ 24.75		$ 25.16
Share-based Payment Arrangement, Expense		$ 696,000	$ 738,000	$ 1,386,000	$ 1,353,000
OPKO [Member] | Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	46,553
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 16.20
Share-based Payment Arrangement, Expense		$ 22,000	$ 37,000	$ 44,000	$ 62,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value							$ 5,300,000
Consulting Agreement, Term	4 years
Consulting Agreement, Term, Length of Automatic Renewal Periods	1 year
Chairman and Chief Executive Officer of OPKO [Member]
Related Party, Ownership Percentage	5.00%

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Aug. 06, 2019	Aug. 02, 2019	Jul. 05, 2019	Jul. 11, 2019	Jun. 30, 2019	Dec. 31, 2018	Dec. 24, 2018
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 6.75
Subsequent Event [Member]
Development Agreement, Upfront Payment Receivable				$ 1,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001
Subsequent Event [Member] | Private Placement Unit [Member]
Debt Conversion, Converted Instrument, Units	210,887
Number of Common Stock in Each Unit	1
Number of Common Stock Called by Each Unit	1
Debt Instrument Conversion Price, Percentage of Price to Public Offering	3.00%
Number of Warrants in Each Unit	1
Subsequent Event [Member] | Public Offering [Member]
Number of Common Stock in Each Unit		1
Number of Common Stock Called by Each Unit		1
Number of Units Offered to Sale		1,666,667
Common Stock, Par or Stated Value Per Share		$ 0.001
Number of Warrants in Each Unit		1
Unit Offering Price		$ 6
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.30
Proceeds from Issuance or Sale of Equity, Gross Amount		$ 10,000,000
Proceeds from Issuance or Sale of Equity, Total		8,760,000
Sale of Units, Offering Expenses, Underwriting Discounts and Commissions		635,000
Underwriting Discounts and Commissions		$ 610,000
Underwriters, Additional Common Shares Authorized to Purchase		250,000
Underwriters, Additional Warrants Authorized to Purchase		250,000
Convertible Promissory Note [Member] | Subsequent Event [Member]
Proceeds from Convertible Debt			$ 625,000
Debt Instrument, Interest Rate, Stated Percentage			14.00%
Debt Conversion, Converted Instrument, Amount	$ 633,000